via Fisher Center
New findings suggest a hormone called Lipocalin-2 could be used as a potential treatment for obesity
A hormone that can suppress food intake and increase the feeling of fullness in mice has shown similar results in humans and non-human primates, says a new study published today in eLife.
The hormone, called Lipocalin-2 (LCN2), could be used as a potential treatment in people with obesity whose natural signals for feeling full no longer work.
LCN2 is mainly produced by bone cells and is found naturally in mice and humans. Studies in mice have shown that giving LCN2 to the animals long term reduces their food intake and prevents weight gain, without leading to a slow-down in their metabolism.
“LCN2 acts as a signal for satiety after a meal, leading mice to limit their food intake, and it does this by acting on the hypothalamus within the brain,” explains lead author Peristera-Ioanna Petropoulou, who was a Postdoctoral Research Scientist at Columbia University Irving Medical Center, New York, US, at the time the study was carried out, and is now at the Helmholtz Diabetes Center, Helmholtz Zentrum München, Munich, Germany. “We wanted to see whether LCN2 has similar effects in humans, and whether a dose of it would be able to cross the blood-brain barrier.”
The team first analysed data from four different studies of people in the US and Europe who were either normal weight, overweight or living with obesity. The people in each study were given a meal after an overnight fast, and the amount of LCN2 in their blood before and after the meal was studied. The researchers found that in those who were of normal weight, there was an increase in LCN2 levels after the meal, which coincided with how satisfied they felt after eating.
By contrast, in people who were overweight or had obesity, LCN2 levels decreased after a meal. Based on this post-meal response, the researchers grouped people as non-responders or responders. Non-responders, who showed no increase in LCN2 after a meal, tended to have a larger waist circumference and higher markers of metabolic disease – including BMI, body fat, increased blood pressure and increased blood glucose. Remarkably, however, people who had lost weight after gastric bypass surgery were found to have a restored sensitivity to LCN2 – changing their status from non-responders before their surgery, to responders afterwards.
Taken together, these results mirror those seen in mice, and suggest that this loss of post-meal LCN2 regulation is a new mechanism contributing to obesity and could be a potential target for weight-loss treatments.
After verifying that LCN2 can cross into the brain, the team explored whether treatment with the hormone might reduce food intake and prevent weight gain. To do this, they treated monkeys with LCN2 for a week. They saw a 28% decrease in food intake compared with that before treatment within a week, and the monkeys also ate 21% less than their counterparts who were treated only with saline. Moreover, after only one week of treatment, measurements of body weight, body fat and blood fat levels showed a declining trend in treated animals.
“We have shown that LCN2 crosses to the brain, makes its way to the hypothalamus and suppresses food intake in non-human primates,” concludes senior author Stavroula Kousteni, Professor of Physiology and Cellular Biophysics at Columbia University Irving Medical Center. “Our results show that the hormone can curb appetite with negligible toxicity and lay the groundwork for the next level of LCN2 testing for clinical use.”
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
Treatment for obesity
- Obesity Management Market is expected to reach US$ 1.3 Billion by 2031
Globally, more than 1 billion individuals are overweight or obese and the numbers continue rising. This high prevalence of obesity will drive demand for obesity management products and services in the ...
- Number of children seeking allergy treatment soars: How to spot one in your child
More and more children are needing medical attention for allergies. Here's how to spot the symptoms and where to get help.
- Sliding backwards in obesity care: Workers see broad reductions and plateauing coverage in state employee health plans
New research published in Obesity has found that multiple state employee healthcare plans have reduced obesity treatment services for workers in the past five years. Conducted by the STOP Obesity ...
- Minimally Invasive Bariatric Procedure Effective for Milder Obesity
Minimally invasive endoscopic sleeve gastroplasty added to lifestyle modifications was effective for inducing significant weight loss, according to the randomized MERIT trial. Among patients with ...
- Estheday Medical Beauty transforms experience and expertise into art following science for the best hair treatment results.
One of the most well-known beauty clinics in Turkey, Estheday Medical Beauty, provides cutting-edge solutions for obesity, plastic surgery, and hair transplantation. California – Aug 1st, 2022 – If ...
Go deeper with Google Headlines on:
Treatment for obesity
Go deeper with Bing News on:
- Role of Biomarkers in the Diagnosis and Prognosis of Acute Kidney Injury in Patients With Cardiorenal Syndrome
Figure 2 illustrates the delay in rise of serum creatinine compared with biomarkers such as B-type natriuretic peptide (BNP) and neutrophil gelatinase-associated lipocalin (NGAL), which rise ...
- Phase 2a clinical trial describes safety and efficacy of dendrimer nanotherapy in severe COVID-19 patients
A multicenter, randomized, placebo-controlled phase 2a clinical trial has recently been conducted to evaluate the efficacy of a nanotherapeutic compound OP-101 in treating severe COVID-19 patients.
- Journal of biological inorganic chemistry
The interaction between lipocalin 2 and dipyridine ketone hydrazone dithiocarbamte may influence respective function in proliferation and metastasis-related gene expressions in HepG2 cell.
- Extracorporeal Kidney-Replacement Therapy for Acute Kidney Injury
It has been suggested that biomarkers such as neutrophil gelatinase–associated lipocalin and the product of tissue inhibitor of metalloproteinase 2 times insulin-like growth factor–binding ...
- Microbiology Virtual Week 2021
Our virtual conference allows you to participate in a global setting with no travel or cost to you. The event will remain open for 2 years from the date of the live event, and the webinars will be ...